While Editas Medicine Inc has overperformed by 0.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EDIT fell by -57.83%, with highs and lows ranging from $11.69 to $2.90, whereas the simple moving average fell by -47.49% in the last 200 days.
On August 08, 2024, BofA Securities Upgraded Editas Medicine Inc (NASDAQ: EDIT) to Buy. A report published by Morgan Stanley on May 09, 2024, Upgraded its rating to ‘Equal-Weight’ for EDIT. Citigroup also Upgraded EDIT shares as ‘Buy’, setting a target price of $11 on the company’s shares in a report dated October 24, 2023. Cantor Fitzgerald October 17, 2023d its ‘Overweight’ rating to ‘Neutral’ for EDIT, as published in its report on October 17, 2023. Stifel’s report from September 29, 2023 suggests a price prediction of $17 for EDIT shares, giving the stock a ‘Buy’ rating. Raymond James also rated the stock as ‘Outperform’.
Analysis of Editas Medicine Inc (EDIT)
Further, the quarter-over-quarter decrease in sales is -82.23%, showing a negative trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Editas Medicine Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -61.23% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.85, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and EDIT is recording an average volume of 1.89M. On a monthly basis, the volatility of the stock is set at 6.69%, whereas on a weekly basis, it is put at 5.50%, with a loss of -8.49% over the past seven days. Furthermore, long-term investors anticipate a median target price of $11.27, showing growth from the present price of $2.91, which can serve as yet another indication of whether EDIT is worth investing in or should be passed over.
How Do You Analyze Editas Medicine Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.94%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 67.17% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
EDIT shares are owned by institutional investors to the tune of 67.17% at present.
